AbbVie (ABBV) Shares are Down -0.14%

AbbVie (ABBV) : During the past 4 weeks, traders have been relatively bearish on AbbVie (ABBV), hence the stock is down -3.76% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.67% relative to the S&P 500. The 4-week change in the price of the stock is -5.71% and the stock has fallen -0.14% in the past 1 week.

The stock has recorded a 20-day Moving Average of 2.17% and the 50-Day Moving Average is 2.68%.The 200 Day SMA reached 6.74% AbbVie Inc. is up 6.36% in the last 3-month period. Year-to-Date the stock performance stands at 9.92%.


AbbVie (ABBV) : 14 Wall Street analysts covering AbbVie (ABBV) believe that the average level the stock could reach for the short term is $72.57. The maximum price target given is $90 and the minimum target for short term is around $47, hence the standard deviation is calculated at $10.61.

For the current week, the company shares have a recommendation consensus of Buy. AbbVie (NYSE:ABBV): stock was range-bound between the intraday low of $63.17 and the intraday high of $63.79 after having opened at $63.53 on Fridays session. The stock finally closed in the red at $63.53, a loss of -0.13%. The stock remained in the red for the whole trading day. The total traded volume was 11,165,269 shares. The stock failed to cross $63.79 in Fridays trading. The stocks closing price on Thursday was $63.27.

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.